Cellectis (ALCLS) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.139x

Based on the latest financial reports, Cellectis (ALCLS) has a cash flow conversion efficiency ratio of -0.139x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.58 Million ≈ $-12.37 Million USD) by net assets (€75.91 Million ≈ $88.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALCLS equity financing ratio to measure how much of total assets are equity-financed.

Cellectis - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how Cellectis's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Cellectis cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Cellectis Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cellectis ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
TRG Latin America Acquisitions Corp. Class A Ordinary Shares NASDAQ:TRGS	-0.002x
Sheng Yu Steel Co Ltd TW:2029	-0.002x
Chicago Atlantic BDC, Inc. NASDAQ:LIEN	0.000x
Hennessy Capital Investment Corp. VII Ordinary Shares NASDAQ:HVII	-0.003x
TERACT EO 1 F:6O8	N/A
DFI Inc TW:2397	0.038x
Principal Capital Public Company Limited BK:PRINC	0.018x
Q Capital Partners Co. Ltd KQ:016600	-0.015x

Annual Cash Flow Conversion Efficiency for Cellectis (2005–2025)

The table below shows the annual cash flow conversion efficiency of Cellectis from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Cellectis (ALCLS) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€75.91 Million ≈ $88.75 Million	€-41.64 Million ≈ $-48.69 Million	-0.549x	-412.69%
2024-12-31	€131.03 Million ≈ $153.19 Million	€22.99 Million ≈ $26.88 Million	0.175x	+160.05%
2023-12-31	€84.69 Million ≈ $99.02 Million	€-24.75 Million ≈ $-28.93 Million	-0.292x	+57.92%
2022-12-31	€125.94 Million ≈ $147.24 Million	€-87.44 Million ≈ $-102.23 Million	-0.694x	-57.03%
2021-12-31	€236.47 Million ≈ $276.46 Million	€-104.56 Million ≈ $-122.24 Million	-0.442x	-70.15%
2020-12-31	€308.85 Million ≈ $361.07 Million	€-80.26 Million ≈ $-93.83 Million	-0.260x	-33.61%
2019-12-31	€355.47 Million ≈ $415.58 Million	€-69.14 Million ≈ $-80.83 Million	-0.195x	-28.54%
2018-12-31	€450.27 Million ≈ $526.41 Million	€-68.14 Million ≈ $-79.66 Million	-0.151x	+17.32%
2017-12-31	€285.90 Million ≈ $334.25 Million	€-52.33 Million ≈ $-61.18 Million	-0.183x	-61.34%
2016-12-31	€274.05 Million ≈ $320.39 Million	€-31.09 Million ≈ $-36.34 Million	-0.113x	-1024.12%
2015-12-31	€288.22 Million ≈ $336.95 Million	€3.54 Million ≈ $4.14 Million	0.012x	-98.25%
2014-12-31	€72.39 Million ≈ $84.63 Million	€50.74 Million ≈ $59.32 Million	0.701x	+118.19%
2013-12-31	€6.65 Million ≈ $7.77 Million	€-25.63 Million ≈ $-29.96 Million	-3.854x	-1105.67%
2012-12-31	€81.69 Million ≈ $95.50 Million	€-26.11 Million ≈ $-30.53 Million	-0.320x	+10.29%
2011-12-31	€37.02 Million ≈ $43.28 Million	€-13.19 Million ≈ $-15.42 Million	-0.356x	+15.35%
2010-12-31	€50.13 Million ≈ $58.60 Million	€-21.10 Million ≈ $-24.67 Million	-0.421x	-337.25%
2009-12-31	€73.22 Million ≈ $85.60 Million	€-7.05 Million ≈ $-8.24 Million	-0.096x	-350.06%
2008-12-31	€46.21 Million ≈ $54.03 Million	€1.78 Million ≈ $2.08 Million	0.038x	+129.82%
2007-12-31	€43.54 Million ≈ $50.91 Million	€-5.62 Million ≈ $-6.57 Million	-0.129x	-400.76%
2005-12-31	€9.11 Million ≈ $10.65 Million	€391.00K ≈ $457.12K	0.043x	--

About Cellectis

PA:ALCLS France Biotechnology

Market Cap

$206.73 Million

€176.83 Million EUR

Market Cap Rank

#16416 Global

#237 in France

Share Price

€2.44

Change (1 day)

+0.41%

52-Week Range

€2.21 - €4.57

All Time High

€40.90